Cost considerations should not drive off-label drug use in the EU
This article was originally published in SRA
Executive Summary
With off-label drug use in the EU moving into the regulatory spotlight, it is becoming clear just how limited member states are in their power to stimulate – or indeed allow – the practice. Peter Bogaert and Armin Schwabl report.